← All candidates
22 insider filings on record.
22 filings on record.
AKTXAkari Therapeutics Plc
NasdaqCM · Healthcare · $19.70M
$10.12
-1.27% today
22 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily◆ 8 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what AKTX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$19.70M
Float
1.3M
65% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
President & CEO
Gaslightwala Abizer
Bought $18.0K on Jun 17 — 15,000 sh @ $1.20, held direct, 5.7% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
17 more transactions on Pro →Context
Wall St
$26.78 avg target
+164.6% vs today · 1 analyst · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
The file stays open
22 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice